Literature DB >> 10631951

The role of H2-O and HLA-DO in major histocompatibility complex class II-restricted antigen processing and presentation.

C Alfonso1, M Liljedahl, O Winqvist, C D Surh, P A Peterson, W P Fung-Leung, L Karlsson.   

Abstract

The function of major histocompatibility complex (MHC) class II molecules is to sample exogenous antigens for presentation to CD4+ T helper cells. After synthesis in the endoplasmic reticulum, class II molecules are directed into the endosomal system by association with the invariant chain (Ii), which is sequentially cleaved, generating class II dimers loaded with Ii-derived peptides (CLIP). These class II-peptide complexes are physiological substrates for H2-M/HLA-DM, a resident of the endosomal/lysosomal system which facilitates the removal of CLIP from newly synthesised class II alpha beta dimers. Exchange of CLIP for antigenic class II-binding peptides is also promoted by the action of H2-M/HLA-DM, resulting in stable peptide-class II complexes that are transported to the cell surface for presentation to CD4+ T cells. Recent evidence suggests that this H2-M/HLA-DM-mediated 'peptide editing' is influenced by another MHC class II-encoded molecule, H2-O/HLA-DO. This non-polymorphic alpha beta heterodimer is associated with H2-M/HLA-DM during intracellular transport and within the endosomal system of B cells. H2-O/HLA-DO alters the peptide exchange function of H2-M/HLA-DM in a pH-dependent manner, so that H2-M/HLA-DM activity is limited to more acidic conditions, corresponding to lysosomal compartments. Indeed, H2-O/HLA-DO may serve to limit the presentation of antigens after fluid phase uptake by B cells, while augmenting presentation of antigens internalised via membrane Ig receptors. Such a mechanism may maintain the fidelity of the B-cell-CD4+ T-cell interaction, counteracting self reactivity arising from less stringent lymphocyte activation. Here, data evaluating the role of H2-O/HLA-DO shall be reviewed and its putative function discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10631951     DOI: 10.1111/j.1600-065x.1999.tb01370.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  8 in total

Review 1.  Diversity in MHC class II antigen presentation.

Authors:  John H Robinson; Alexei A Delvig
Journal:  Immunology       Date:  2002-03       Impact factor: 7.397

2.  TLR agonists downregulate H2-O in CD8alpha- dendritic cells.

Authors:  Gavin W Porter; Woelsung Yi; Lisa K Denzin
Journal:  J Immunol       Date:  2011-09-14       Impact factor: 5.422

3.  TLR-mediated B cell activation results in ectopic CLIP expression that promotes B cell-dependent inflammation.

Authors:  M K Newell; R P Tobin; J H Cabrera; M B Sorensen; A Huckstep; E M Villalobos-Menuey; M Burnett; E McCrea; C P Harvey; A Buddiga; A Bar-Or; M S Freedman; J Nalbantoglu; N Arbour; S S Zamvil; J P Antel
Journal:  J Leukoc Biol       Date:  2010-07-14       Impact factor: 4.962

Review 4.  MHC class II antigen presentation and immunological abnormalities due to deficiency of MHC class II and its associated genes.

Authors:  Xinjian Chen; Peter E Jensen
Journal:  Exp Mol Pathol       Date:  2008-04-13       Impact factor: 3.362

5.  Oxidative stress impairs intracellular events involved in antigen processing and presentation to T cells.

Authors:  Olivier Preynat-Seauve; Sylvia Coudurier; Alain Favier; Patrice-Noël Marche; Christian Villiers
Journal:  Cell Stress Chaperones       Date:  2003       Impact factor: 3.667

6.  Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy.

Authors:  Jacques Thibodeau; Marie-Claude Bourgeois-Daigneault; Réjean Lapointe
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

7.  DM determines the cryptic and immunodominant fate of T cell epitopes.

Authors:  N K Nanda; A J Sant
Journal:  J Exp Med       Date:  2000-09-18       Impact factor: 14.307

8.  Negative selection in tumor genome evolution acts on essential cellular functions and the immunopeptidome.

Authors:  Luis Zapata; Oriol Pich; Luis Serrano; Fyodor A Kondrashov; Stephan Ossowski; Martin H Schaefer
Journal:  Genome Biol       Date:  2018-05-31       Impact factor: 13.583

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.